AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Axial Spondyloarthritis: World Markets & Epidemiology Forecast to 2028 - ResearchAndMarkets.com

October 30, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Oct 30, 2019--

The “Axial Spondyloarthritis - Epidemiology Forecast to 2028” report has been added to ResearchAndMarkets.com’s offering.

The author epidemiologists selected nationally representative population-based studies that provided data for the diagnosed prevalence of AxSpA in the 7MM. The author’s epidemiological analysis provides country-specific forecast for the diagnosed prevalent cases of AS and nr-AxSpA in the 7MM during 2018-2028 using two different approaches: forecast based on data obtained through primary market research (PMR) (base scenario), and forecast based on data obtained from secondary research (alternate scenario).

The following data describes diagnosed prevalent cases of AS and nr-AxSpA in the 7MM using base scenario, where the forecast is based on data obtained from PMR. In the 7MM, the diagnosed prevalent cases of AS will increase from 1,393,906 cases in 2018 to 1,788,563 cases in 2028, at an Annual Growth Rate (AGR) of 2.83% and the diagnosed prevalent cases of nr-AxSpA will increase from 1,003,767 cases in 2018 to 1,328,882 cases in 2028, at an AGR of 3.24%.

Scope

Reasons to Buy

The AxSpA Epidemiology series will allow you to:

Key Topics Covered

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Axial Spondyloarthritis: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Base Scenario

3.4.3 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-AxSpA - Base Scenario

3.4.4 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Alternative Scenario

3.4.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-AxSpA - Alternative Scenario

3.4.6 Forecast Assumptions and Methods, HLA-B27 Seropositivity Among Diagnosed AS Patients

3.5 Epidemiological Forecast for AS and Nr-AxSpA (2018-2028) - Base Scenario

3.5.1 Diagnosed Prevalent Cases of AS

3.5.2 Diagnosed Prevalent Cases of Nr-AxSpA

3.6 Epidemiological Forecast for AS and Nr-AxSpA (2018-2028) - Alternative Scenario

3.6.1 Diagnosed Prevalent Cases of AS

3.6.2 Age-Specific Diagnosed Prevalent Cases of AS

3.6.3 Sex-Specific Diagnosed Prevalent Cases of AS

3.6.4 Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity

3.6.5 Diagnosed Prevalent Cases of Nr-AxSpA

3.6.6 Age-Specific Diagnosed Prevalent Cases of Nr-AxSpA

3.6.7 Sex-Specific Diagnosed Prevalent Cases of Nr-AxSpA

3.7 Discussion

3.7.1 Epidemiological Forecast Insight

3.7.2 Limitations of the Analysis

3.7.3 Strengths of the Analysis

4 Appendix

4.1 Bibliography

4.2 Primary Research - Prescriber Survey

4.3 Abbreviations

4.4 About the Authors

4.4.1 Epidemiologist

4.4.2 Reviewers

4.4.3 Global Director of Therapy Analysis and Epidemiology

4.4.4 Global Head and EVP of Healthcare Operations and Strategy

For more information about this report visit https://www.researchandmarkets.com/r/uh2cvx

View source version on businesswire.com:https://www.businesswire.com/news/home/20191030005681/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 10/30/2019 11:12 AM/DISC: 10/30/2019 11:12 AM

http://www.businesswire.com/news/home/20191030005681/en